IXICO PLC Total Assets

Latest as of March 2026: GBX12.99 Million GBX ≈ $1.58K USD

IXICO PLC total assets. Based on the latest financial reports, IXICO PLC (IXI) holds total assets worth GBX12.99 Million GBX (≈ $1.58K USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see IXICO PLC stock valuation for the company's overall valuation and market capitalisation.

Total Assets of IXICO PLC (1993–2025)

Total assets of IXICO PLC from 1993 to 2025. This chart illustrates how IXICO PLC's total assets have evolved over time, based on quarterly financial data. See IXICO PLC stock price for real-time trading data and today's change.

IXICO PLC - Asset Composition Analysis

IXICO PLC Total Assets Breakdown (September 2025)

IXICO PLC total assets breakdown as of September 2025. IXICO PLC's total assets of GBX12.99 Million consist of 45.1% current assets and 55.0% non-current assets.

Asset Category Amount (GBX) % of Total Assets
Cash & Equivalents GBX0.00 25.6%
Accounts Receivable GBX2.70 Million 19.5%
Inventory GBX0.00 0.0%
Property, Plant & Equipment GBX0.00 0.0%
Intangible Assets GBX7.18 Million 51.9%
Goodwill GBX0.00 0.0%

Asset Composition Trend (1993–2025)

This chart illustrates how IXICO PLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is IXICO PLC's working capital to assess how much short-term liquidity the company maintains relative to its equity base.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: IXICO PLC's current assets represent 45.1% of total assets in 2025, a decrease from 79.5% in 1993.
  • Cash Position: Cash and equivalents constituted 25.6% of total assets in 2025, up from 15.7% in 1993.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 51.0% of total assets, an increase from 0.0% in 1993.
  • Asset Diversification: The largest asset category is intangible assets at 51.9% of total assets.

IXICO PLC Competitors by Total Assets

Key competitors of IXICO PLC based on total assets are shown below.

Company Country Total Assets
Hyloris Developmentsen Sa
BR:HYL
Belgium €37.05 Million
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
USA $11.72 Billion
Oruka Therapeutics, Inc.
NASDAQ:ORKA
USA $1.14 Billion
Gempharmatech Co. Ltd. A
SHG:688046
China CN¥2.80 Billion
Vor Biopharma Inc
NASDAQ:VOR
USA $481.05 Million
Inventiva S.A
PA:IVA
France €249.51 Million
Sunmax Biotechnology Co Ltd
TWO:4728
Taiwan NT$1.90 Billion
Apnimed, Inc. Common Stock
NASDAQ:APMD
USA $342.63 Million

IXICO PLC - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 2.83 4.28 4.64
Quick Ratio 2.83 4.28 4.64
Cash Ratio 0.00 0.00 0.00
Working Capital GBX3.30 Million GBX5.59 Million GBX8.20 Million

IXICO PLC - Advanced Valuation Insights

This section examines the relationship between IXICO PLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 1.51
Latest Market Cap to Assets Ratio 0.03
Asset Growth Rate (YoY) 23.7%
Total Assets GBX13.84 Million
Market Capitalization $412.96K USD

Valuation Analysis

Below Book Valuation: The market values IXICO PLC's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.

Rapid Asset Growth: IXICO PLC's assets grew by 23.7% over the past year, indicating significant expansion of the company's resource base.

Annual Total Assets for IXICO PLC (1993–2025)

The table below shows the annual total assets of IXICO PLC from 1993 to 2025.

Year Total Assets Change
2025-09-30 GBX13.84 Million
≈ $1.68K
+23.70%
2024-09-30 GBX11.19 Million
≈ $1.36K
-13.87%
2023-09-30 GBX12.99 Million
≈ $1.58K
-11.36%
2022-09-30 GBX14.65 Million
≈ $1.78K
+2.77%
2021-09-30 GBX14.26 Million
≈ $1.74K
+17.89%
2020-09-30 GBX12.10 Million
≈ $1.47K
+13.04%
2019-09-30 GBX10.70 Million
≈ $1.30K
+3.50%
2018-09-30 GBX10.34 Million
≈ $1.26K
+129.30%
2017-09-30 GBX4.51 Million
≈ $548.61
-20.64%
2016-09-30 GBX5.68 Million
≈ $691.34
+34.04%
2015-09-30 GBX4.24 Million
≈ $515.76
-21.69%
2014-09-30 GBX5.41 Million
≈ $658.61
+5.05%
2013-09-30 GBX5.15 Million
≈ $626.97
-51.34%
2012-09-30 GBX10.59 Million
≈ $1.29K
-43.06%
2011-09-30 GBX18.60 Million
≈ $2.26K
-24.44%
2010-09-30 GBX24.61 Million
≈ $2.99K
+404.05%
2009-09-30 GBX4.88 Million
≈ $594.12
-42.51%
2008-09-30 GBX8.49 Million
≈ $1.03K
+104.48%
2007-09-30 GBX4.15 Million
≈ $505.42
-49.44%
2006-08-31 GBX8.22 Million
≈ $999.65
-41.62%
2005-08-31 GBX14.07 Million
≈ $1.71K
+86.37%
2004-08-31 GBX7.55 Million
≈ $918.74
+9.24%
2003-08-31 GBX6.91 Million
≈ $840.99
-43.52%
2002-08-31 GBX12.24 Million
≈ $1.49K
-13.62%
2001-08-31 GBX14.17 Million
≈ $1.72K
+148.15%
2000-08-31 GBX5.71 Million
≈ $694.62
+78.46%
1999-08-31 GBX3.20 Million
≈ $389.23
-14.12%
1998-08-31 GBX3.73 Million
≈ $453.22
-48.54%
1997-08-31 GBX7.24 Million
≈ $880.66
-27.15%
1996-08-31 GBX9.94 Million
≈ $1.21K
+2830.68%
1995-08-31 GBX339.00K
≈ $41.25
+80.32%
1994-08-31 GBX188.00K
≈ $22.87
-58.50%
1993-08-31 GBX453.00K
≈ $55.12
--

About IXICO PLC

LSE:IXI UK Biotechnology
Market Cap
$412.96K
GBX3.39 Billion GBX
Market Cap Rank
#31134 Global
#947 in UK
Share Price
GBX15.50
Change (1 day)
+10.71%
52-Week Range
GBX6.63 - GBX15.50
All Time High
GBX123.50
About

IXICO plc provides data analytics services to biopharmaceutical industry in the United States, the United Kingdom, the Netherlands, Denmark, Switzerland, Ireland, Europe, and internationally. The company offers collection, analysis, management, and reporting on gathered clinical study data; neurological diseases data collection and analysis; and sales and marketing services. It also provides imag… Read more